Suven Pharma zooms 12% on merger with Cohance Lifesciences

On February 7, 2024, Moneycontrol was the first to report that leading global private equity fund Advent International had initiated the merger process for its portfolio companies Suven Pharmaceuticals and Cohance Lifesciences and picked Kotak Mahindra Capital and Citi as advisors for deal aspects like swap ratio, due diligence and fairness opinion.

The merger will establish Suven as a diversified CDMO and API leader in India, expnnding its revenue base, the company told exchanges. The merged entity is expected to be amongst the leading integrated CDMO players in India.

With an expanded capacity of 2,650 kL and a significantly broadened customer base, scale and synergy benefits would be substantial.

Upon the scheme becoming effective, all shareholders of Cohance will be issued shares of Suven in the ratio of 11 shares of Suven for every 295 shares of Cohance, based on the swap ratio. The new shares of Suven will trade on NSE as well as BSE.

Advent will own 66.7 percent and the public shareholders will hold 33.3 percent of the combined entity (pre-ESOP dilution).

Also Read | Suven Pharma, Cohance Lifesciences announce merger

At 10.13 am, Suven Pharma shares were trading nearly 10 percent higher at Rs 694.55 on the National Stock Exchange. In the last year, the stock has jumped around 45 percent against as a 27 percent rise in the Nifty.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.